Expression of the serine rich Entamoeba histolytica protein (SREHP) in the avirulent vaccine strain Salmonella typhi TY2 chi 4297 (delta cya delta crp delta asd): safety and immunogenicity in mice.
Infection by the intestinal protozoan parasite Entamoeba histolytica remains a significant threat to health in much of the world. Here we describe the successful expression of the serine rich Entamoeba histolytica protein (SREHP), a protective antigen of ameba, in an attenuated vaccine strain Salmonella typhi TY2 chi 4297 (delta cya delta crp delta asd). The attenuation of S. typhi TY2 chi 4297 was not altered by expression of the SREHP-maltose binding protein (MBP) fusion protein and mice parenterally vaccinated with S. typhi TY2 chi 4297 expressing SREHP-MBP developed serum anti-amebic and anti-LPS antibodies. S. typhi TY2 chi 4297 expressing SREHP-MBP represents a prototype combination vaccine designed to prevent both amebiasis and typhoid fever.
Zhang
T
T
Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA.
Stanley
S L
SL
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology*; D004748:Entamoeba histolytica / Q000276:immunology*; D051379:Mice; D016052:Protozoan Vaccines / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology; D012485:Salmonella typhi / Q000235:genetics*; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology* / Q000633:toxicity
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D016052:Protozoan Vaccines; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic